/
Oncology
Urothelial Carcinoma
110
Pipeline Programs↗
155
Active Trials↗
79
Companies Involved↗
Urothelial Carcinoma is a highly competitive landscape with 110 programs across 79 companies. The most active players are Merck & Co., Sichuan Baili Pharmaceutical Co., Ltd., AbbVie. 24 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical19
Phase 117
Phase 250
Phase 324
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
71 of 98 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 98 classified programs, each share of the total. Modality classified for 95% of 110 pipeline programs.
Analysis
Trial Status
374
clinical trials
Completed108 · 29%
Recruiting82 · 22%
Terminated55 · 15%
Active, not recruiting53 · 14%
Unknown status34 · 9%
Not yet recruiting20 · 5%
Other22 · 6%
Clinical Trials
Trial Activity
374 trials
Page 1 of 25
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)